Valeant Pharmaceuticals International (VRX) Shares are Down -1.52%

Valeant Pharmaceuticals International (VRX) : During the past 4 weeks, traders have been relatively bearish on Valeant Pharmaceuticals International (VRX), hence the stock is down -7.84% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.94% relative to the S&P 500. The 4-week change in the price of the stock is -5.55% and the stock has fallen -1.52% in the past 1 week.

Valeant Pharmaceuticals International (NYSE:VRX): The stock opened at $22.14 on Friday but the bulls could not build on the opening and the stock topped out at $22.27 for the day. The stock traded down to $21.90 during the day, due to lack of any buying support eventually closed down at $21.96 with a loss of -1.26% for the day. The stock had closed at $22.24 on the previous day. The total traded volume was 11,437,463 shares.

The stock has recorded a 20-day Moving Average of 3.99% and the 50-Day Moving Average is 6.47%. Valeant Pharmaceuticals International, Inc. has dropped 26.53% during the last 3-month period . Year-to-Date the stock performance stands at -78.4%.

Valeant Pharmaceuticals International (VRX) : Average target price received by Valeant Pharmaceuticals International (VRX) is $39.75 with an expected standard deviation of $19.53. The most aggressive target on the stock is $90, whereas the most downbeat target is $11. 12 financial analysts are currently covering the stock.


Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.